Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Clinical trial NCT06700343 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06700343
Sponsor: Amgen
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsing-remitting Multiple Sclerosis (RRMS)

Start date: 2025-01-13
Primary completion: 2027-04-19
Enrollment: 152

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.